Introduction
Owing to their diverse roles in many physiological and pathophysiological settings, G-protein-coupled receptors (GPCRs) represent important drug targets. Pharmacological characterization of GPCR ligands has traditionally focused on potency and efficacy, where concentration-dependent parameters are measured at (or near) equilibrium. There is, however, a growing appreciation for the clinical relevance of the temporal aspects of ligand-receptor interactions [1, 2] .
Optimizing the properties of GPCR agonists to have a long duration of action could seem like an attractive drug discovery strategy, by increasing target activation and thereby improving clinical efficacy, as has been highlighted for antagonists [1, 2] . However, historical data and perceived wisdom suggest that agonist responses are usually regulated by receptor desensitization and internalization, which can act to limit the effect and duration of receptor signaling. Therefore, the anticipated effects of prolonged agonist binding could be negated by a loss of receptor function.
Nevertheless, it is becoming increasingly apparent that desensitization does not always play a major regulatory part, and in some cases downstream G-protein responses persist for extended periods of time during continual agonist exposure (Table 1 lists current examples). These findings suggest that the opportunity can exist for a long duration of action to be specifically optimized through understanding and targeting ligand-specific factors that promote persistent agonist-receptor interactions. In this review, we discuss the mechanisms proposed for sustained wash-resistant receptor responses and evaluate the importance of ligand-dependent properties such as slow dissociation kinetics and rebinding in driving these effects. We conclude by highlighting the potential value in targeting sustained signaling for future drug discovery programs.
Sustained GPCR signaling
The classic model of GPCR function describes tightly regulated responses that undergo desensitization and internalization upon chronic agonist exposure. This typically involves phosphorylation of agonist-activated receptors by G-protein-coupled receptor kinases (GRKs) and/or other intracellular protein kinases followed by recruitment of b-arrestin, as reviewed elsewhere [3, 4] . However, it now appears that not all GPCRs interact with b-arrestin [5] [6] [7] . It is possible that these receptors can therefore avoid conventional desensitization mechanisms and demonstrate persistent agonist responses from cell-surface, noninternalized receptors (Table 1) .
To add further complexity, and in complete contrast to this classic understanding of receptor internalization as a mechanism for negatively regulating receptor responses, it has been demonstrated that some GPCRs can continue to signal after internalization. This sustained signaling by internalized receptors (SSIR) permits prolonged G-protein signaling from intracellular compartments (often endosomes). Ferrandon and colleagues [8] used real-time cAMP measurements in conjunction with imaging of fluorescently labeled receptors to measure the dynamics of parathyroid hormone (PTH) receptor signaling and trafficking. These studies demonstrated that, contrary to initial expectations, cAMP signaling was not diminished when there was a concurrent loss of cell-surface receptors by internalization. Instead, receptors colocalized with the necessary signaling machinery in endosomes post agonist stimulation and, remarkably, inhibition of endocytosis reduced cAMP responsiveness.
SSIR has also been reported for a number of other diverse GPCR subtypes (Table 1) , perhaps indicating that this phenomenon can in fact represent a more widespread mechanism of GPCR function.
Not only can SSIR promote extended receptor responses but there is also evidence that G-protein signals generated from intracellular compartments can be functionally distinct from those at the cell surface [9, 10] . Moreover, internalization can also facilitate sustained G-protein-independent mitogen-activated protein kinase (MAPK) signaling by GPCRs [11, 12] . Internalization can therefore have a significant impact on the regulation and functional outcomes of receptor signaling.
Does the agonist need to be there?
Surprisingly, a gap in our basic understanding of GPCR function is related to the role of the agonist after it has activated the receptor.
It might seem intuitive that throughout the duration of signaling the receptor must be in a continual agonist-bound activated state, but there is little direct evidence for this.
Clues toward whether agonist-receptor binding remains intact after endocytosis come from studies examining the subcellular localization of fluorescently tagged agonists and receptors. A number of peptide agonists have been demonstrated to co-internalize and intracellularly co-localize with their cognate receptors [8, 9, 13] . This has also been observed for small-molecule adrenergic and adenosinergic receptor agonists [14, 15] . Furthermore, realtime whole-cell binding experiments with PTH receptor demonstrated that the agonist remained receptor-bound throughout the time-course of sustained endosomal responses, despite the loss of cell-surface receptors by internalization [8] .
Strong evidence for functional consequences of post-endocytic binding interactions comes from studies examining the influence of enzymatic degradation of neurokinin-1 receptor agonists [12] . An endosomal agonist-receptor-b-arrestin complex that signals through MAPK is terminated by degradation of the agonist within endosomes, suggesting a requirement for continual binding in these compartments.
Ligand properties that favor persistent receptor interactions
If continual agonist binding is required for sustained signaling then it is likely that these responses will be facilitated by agonistspecific properties that prolong interactions with the receptor. Using in vitro experiments this can be exhibited by 'wash-resistant' receptor activation, where signaling continues even after excess agonist is removed from the receptor by infinite dilution of the drug-containing buffer [8, 9, [16] [17] [18] [19] [20] [21] [22] . It is anticipated that this could Drug Discovery Today Volume 21, Number 1 January 2016 REVIEWS [21, 38] Abbreviations: GPCR, G-protein-coupled receptor; SSIR, sustained signaling by internalized receptors; n.d., not determined. a The duration of sustained effect as defined by a significant level of receptor activation that remains after washout of agonist. b The duration of sustained effect as defined by a significant level of receptor activation that remains after chronic continual agonist treatment.
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translate to sustained in vivo receptor activation that endures clearance from the body. We have identified the main mechanisms that can explain persistent activation, which are also summarized in Fig. 1 . i Residence time. This describes the duration of ligand-receptor interactions. Long residence time could drive sustained receptor activation through a single preformed stable binding event that persists after removal of unbound agonist (Fig. 1a) , as has been implicated for a number of GPCR agonists [18, 20, 22, 23] . In the simplest model, ligand binds to receptor to form ligand-receptor complexes and, in binding kinetic experiments, residence time is calculated at the reciprocal of the rate of dissociation (K off ) of these complexes (Eqn 1).
ii Rebinding. This describes a phenomenon where, upon receptor dissociation, a ligand is more likely to bind again rather than diffuse away and discontinue its influence [24] ( Fig. 1b) . Therefore, rather than persistent occupation of the binding site per se, factors that hinder the removal of the ligand from the vicinity of the receptor can also cause prolonged effects through promoting the opportunity for multiple new binding events after removal of excess ligand. This could be linked to physiochemical properties of the ligand because lipophilic compounds can partition into cellular membranes and subsequently access the receptorbinding site from (or through) the membrane environment after removal of free agonist in the aqueous phase. Sustained agonist effects via this mechanism have been suggested for the b2-adrenergic receptor [25, 26] and GPR119 [22] . iii Exosite. An exosite hypothesis ( Fig. 1c) has also been proposed for long-acting b2-adrenerigc agonists [27] as well as the muscarinic M1 agonist xanomeline [21] , and can be viewed as an extreme example of rebinding. This involves one part of the ligand persistently interacting with a secondary binding site on or near the receptor (the 'exosite'), bringing the pharmacologically active head group into the proximity of the receptor-binding site and allowing multiple cycles of dissociation and reassociation. iv SSIR. Agonist-driven receptor internalization promotes signaling from intracellular compartments (Fig. 1d) . Internalization can allow a more prolonged agonist response [8, 9] , perhaps by avoiding conventional cell-surface desensitization mechanisms.
Ligand properties driving SSIR
Clearly, the ability of a given agonist to promote SSIR will depend on its ability to cause receptor internalization. However, is it sufficient for an agonist to drive internalization for it to evoke SSIR; or can other ligand-specific factors that influence the durability of ligand binding effect the generation and maintenance of SSIR? In other words, are binding kinetics and rebinding still important phenomena in controlling the duration of signaling from internalized receptors, as they are for those receptors at the cell surface? Anecdotal evidence suggests that agonist dissociation kinetics can regulate whether a ligand can evoke SSIR. For PTH receptor, calcitonin and serotonin 5-HT2B receptors the observation of SSIR appears to be characteristic of agonists with slow dissociation from these receptors, while being absent with rapidly dissociating ligands [8, 18, 19] . It is therefore tempting to speculate that long residence time is a general feature of SSIR agonists, although this remains to be characterized for other receptors. However, additional evidence suggests that long residence time alone is not sufficient to support SSIR but that rebinding is also important. The duration of SSIR measured for 5-HT2B agonists is longer than their residence times [19] , suggesting that multiple independent binding events are likely to be involved (i.e. a single binding event is not sufficiently long). Moreover, SSIR observed for 5-HT2B and sphingosine-1 phosphate (S1PR) receptors can be reversed with antagonists [16, 19] . This can be considered a hallmark of rebinding 
and thus indicates agonist dissociation events during the generation of sustained responses, assuming that the antagonists used are orthosteric and capable of passing cellular membranes to access intracellular receptor-binding sites. Because of the 'outside in' nature of membrane rearrangements during endocytosis, internalized agonists will be found inside intracellular compartments (Fig. 1d) . This can result in increased local concentrations of the agonist as it is trapped within a spatially confined yet receptor-enriched environment, promoting opportunities for rebinding events [28] .
Residence time and rebinding could interact to regulate SSIR, thus explaining how slow dissociation kinetics is important but not sufficient for it. Interestingly, there is evidence linking agonist off-rate with an ability to induce S1PR endocytosis-dependent responses and that the agonist must be bound long enough to co-internalize with the receptor [29] . It is plausible that a threshold residence time is required for agonist-receptor co-internalization events and subsequently the generation of SSIR. We speculate that a single binding event can be sufficient to initiate SSIR, but it is maintained by multiples of these events (rebinding) to exacerbate response duration.
Model: residence time regulates SSIR
Based on the literature and internal unpublished observations, we have proposed a model to help understand the contribution of residence time and rebinding for SSIR. Figure 2a describes a hypothetical receptor system that displays agonist-driven internalization with a half-life of 3 min, which represents a typical GPCR endocytic rate based on observations in the literature [8, 30, 31] . The receptor system also has the capacity for receptor signaling from intracellular compartments. We speculate that the residence time of an agonist relative to receptor internalization rate will determine the proportion of agonist co-internalized with the receptor. Based on measurements made at 378C for multiple receptor systems, GPCR ligands have been observed to have residence times ranging from less than a minute to a number of hours [8, 18, 23, 32, 33] . In this model we describe ligands that fall within this range. Agonist A has a residence time of 10 min and therefore remains bound for sufficient time to internalize in a complex with the receptor (Fig. 2b) . This results in a continued ability to activate the receptor from intracellular compartments (SSIR). By contrast, agonist C has a residence time of 1 min, so significantly shorter Drug Discovery Today Volume 21, Number 1 January 2016 REVIEWS Model that predicts how sustained signaling by internalized receptors (SSIR) depends on agonist residence time by regulating agonist-receptor co-internalization in a hypothetical receptor system. (a) The red line on the graph shows the rate of receptor internalization after commencement of agonist exposure (t½ = 3 min). The blue bars superimposed onto this represent the residence times of three agonists: 10, 5 and 1 min for agonists A, B and C, respectively. Comparing receptor internalization rate with residence time it can be seen that agonist A remains bound when the majority of receptors are internalized, agonist C remains bound when only a small proportion are internalized and agonist B is intermediate. (b) For agonist A, therefore, robust co-internalization of agonist-receptor complexes occurs. This permits activation of the receptor from endosomes after internalization, thus eliciting SSIR. It can be seen that once this has occurred the agonist is trapped within endosomes, which is predicted to promote rebinding and prolong the effects of the ligand. Agonist B will elicit a partial SSIR response as a lower level of agonist-receptor co-internalization will occur. (c) By contrast, agonist C does not co-internalize with the receptor to the same extent and can therefore not evoke SSIR. The functional consequences of these differences are linked to qualitative differences in the signaling pathways through which the receptor signals based on its subcellular localization: G-proteins X and Y and MAPK, as well as the duration of activation thereof.
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www.drugdiscoverytoday.com 93 than the internalization half-life, and therefore dissociates before most of the receptors have internalized, preventing it from accessing these signaling cascades (Fig. 2c) .
Therefore, the outcomes of activation by agonists A and C are predicted to be functionally distinct as a consequence of whether their dissociation kinetics are slow enough to meet the threshold residence time required for co-internalization with the receptor. As well as evoking more-prolonged signaling, agonist A might be further differentiated via activation of qualitatively different G-protein cascades (X and Y in Fig. 2) , and the ability to access endosomal MAPK pathways.
Once SSIR is initiated, the agonist is spatially confined within intracellular compartments, enriching its local concentration and therefore increasing the potential to bind to the receptor multiple times (i.e. rebinding). Importantly, this could maintain a response duration that is far longer than that governed by a single binding event (i.e. purely residence-time-driven). To reiterate, we predict that residence time can regulate whether or not SSIR is triggered, but the duration of the response can be subsequently influenced by rebinding events.
Because there is limited published experimental data available to verify the relationship between agonist residence time and agonist-receptor co-internalization, this model is speculative. We therefore propose the following approaches to test the assumptions of the model. First, a direct comparison of receptor internalization rates and ligand-binding kinetics for a panel of agonists will be crucial. Second, an assessment of putative correlations between GPCR agonist residence time and the observation of agonist-receptor co-internalization events will be key to understanding whether a threshold residence time is required. This could be achieved by co-imaging fluorescently tagged ligands and receptors. Third, proposed post-internalization intracellular agonist-receptor binding could potentially be monitored by adapting current Förster resonance energy transfer (FRET)-based whole-cell binding assays [8, 34, 35] under conditions of endocytosis inhibition or by selectively removing cell-surface FRET signals. Fourth, the role of rebinding could be assessed by applying wellcharacterized cell-permeant orthosteric antagonists to disrupt intracellular agonist binding or signaling, while comparing the effect of cell-inpermeant antagonists. And, finally, where there has been clear demonstration of ligand-specific SSIR, such as in the case of vasopressin and oxytocin at the vasopressin V2 receptor [17] , we propose intriguing follow-up studies to compare the binding kinetics of these ligands directly.
Relevance to clinical efficacy
Long duration of action (preferably 24 hours) is an important feature of drugs intended to treat chronic illness, and there is evidence that this could be achieved for GPCR antagonists via long residence time, thus improving their clinical efficacy [1] . However, despite a prominent role for many GPCR agonists in the clinic, the relevance of residence time for these ligands remains poorly understood.
If the outcome and duration of receptor responses to agonists can be influenced by residence time, this offers the exciting opportunity to exploit binding kinetics to optimize the temporal and functional response profiles of future drug candidates. Thus, a more selective pharmacotherapeutic response could be targeted to improve clinical efficacy and safety. For example, a long or short duration of action might be preferred or only part of the response repertoire of the receptor activated. Although prolonged receptor effects are likely to be advantageous in many cases, it must also be considered that developing drugs with a shorter duration of action could be preferential where target-based toxicity is a problem [1] . Thus, under some circumstances, optimizing a lack of SSIR might provide a better drug candidate.
Interestingly, long-and short-acting PTH receptor agonists have been proposed to have distinct potential clinical applications (hypoparathyroidism and osteoporosis, respectively) based on their differences to evoke SSIR [36] , whereas SSIR of ergot 5-HT2B agonists has been postulated to confer cardiac valvulopathic side effects of these ligands [19] . Moreover, the clinical efficacy of the S1P1R immunomodulator drug FTY729P is proposed to be linked to its long residence time that promotes persistent receptor internalization and intracellular signaling [29] . Importantly, SSIR has been observed for a growing list of endogenous ligands [9, 17, 37] , highlighting its potential physiological relevance.
Relevance to drug discovery approaches
Can we develop agonists that selectively promote sustained signaling? In support of the potential to optimize this property, differences in the ability of agonists to evoke sustained signaling for the same receptor have been observed in a number of cases [8, [17] [18] [19] [20] 22, 38] . This highlights the general ability to drive divergent receptor responses in a ligand-selective manner. However, before these properties can be optimized in a predictable and strategic manner it will be important to develop a more detailed understanding of the mechanisms behind differentiated agonist response profiles. For example, GPR119 agonists differ not only in their ability to cause sustained activation but also in the ligand-specific properties that cause the effect (residence time vs membrane deposition) [22] . Interestingly, efforts have been made to understand the SAR of the sustained effects of derivatives of the muscarinic M1 agonist xanomeline, identifying potential roles for hydrophobic interactions as well as exosite binding [38] . Similarly, a comparison of S1P1R agonists identified structural features that correlate with the observation of SSIR [16] . Notably, the ability to predict structure-kinetic relationships for GPCR agonists has recently been reported, which could assist future targeting of long residence time agonist compounds [39] . It is anticipated that the emerging structural understanding of receptor-ligand interactions driven by X-ray crystallization techniques will significantly increase our understanding GPCR biology, which could indirectly inform strategies to optimize ligandbinding kinetics.
GPCR ligand-binding kinetics are too infrequently characterized, and only with more kinetic information can we better understand and validate the role of agonist residence time in regulating receptor function. We suggest that a number of important considerations might be required to define agonist residence time and SSIR properties fully.
i Putative receptor binding in intracellular compartments during SSIR might not be equivalent to binding at the cell surface because of the vast differences between the two environments (e.g. space, pH, receptor density, receptor regulatory states and protein-protein interactions).
ii Currently, measurements of residence time are largely made in noncellular systems, at below-physiological temperature, and/ or where no distinction is made between surface and internalized receptors. iii Whole-cell binding experiments performed at 378C could provide more-appropriate kinetic information than membrane fractions tested at low temperature. FRET-based ligandbinding assays, as previously applied [8, 34, 35] , could be especially useful for whole-cell approaches because the binding signal is specific for ligand-receptor interactions without the need to wash unbound ligand. Therefore, binding can be detected from the cell surface and intracellular receptors after internalization events. iv It might also be important to measure residence time at pH relevant to intracellular compartments (e.g. pH < 6.5 for endosomes). v Because SSIR is likely to be cell-context-dependent, highly artificial recombinant expression systems might not accurately predict in vivo responses. Studying physiologically relevant systems such as primary cell lines or induced stem cell models along with phenotypic screening approaches could be beneficial and more appropriate for defining this mechanism of action. An attractive extension to our hypothesis is to consider that differences between agonists in driving sustained signaling can be viewed as a form of ligand bias, which has attracted much attention in drug discovery. Ligand bias is proposed to involve conformationally selective ligand binding to differentially promote signaling from multiple active receptor states [40] . However, some classic observations of ligand bias (e.g. selective MAPK signaling) could be explained in part by residence time: how and where the receptor signals are being controlled by agonist binding kinetics (Fig. 2 ). It will be interesting to observe how the concepts of ligand bias and residence time develop with future understanding.
Ultimately, the relevance of SSIR will only be fully understood by testing agonists with different signaling properties in relevant in vivo models. This also requires the impact of pharmacokinetics to be considered. The majority of in vitro receptor assays are performed under equilibrium conditions, which might not wholly represent dynamic changes in ligand concentrations in vivo. A recent model has highlighted that residence time can only influence in vivo duration of action if dissociation rate is slower than elimination from the body [41] . Whereas this holds true for antagonists, where the duration of binding is equal to the duration of effect, GPCR agonist effects are inherently more complex because of the spatiotemporal dynamics of receptor activation. Because residence time is predicted to regulate receptor signaling qualitatively it could operate somewhat independently of pharmacokinetics. Moreover, long residence time that allows endosomal co-localization and rebinding could exaggerate effect duration long after extracellular elimination.
Concluding remarks
Recent observations that GPCR signaling can be stable over time have highlighted the importance of temporal aspects of agonistresponse profiles. It remains unclear how agonist-specific properties might influence sustained responses. However, a better understanding of the interdependence of persistent ligand binding and sustained receptor activation would offer greater clarity into the pharmacological regulation of receptor activation. Consequently, these phenomena could be selectively optimized and exploited for drug discovery to achieve more selective ligand response profiles. We envision that strategies to optimize agonist residence time represent an appealing approach to target (or avoid) sustained GPCR signaling selectively.
Here, we have theoretically examined how agonist residence time can regulate SSIR, and highlighted experimental evidence to support this. As an overview of the literature, it appears that, where it has been tested, slow receptor dissociation is a characteristic feature of agonists that elicit SSIR. However, this property remains to be verified with a larger panel of agonist-receptor pairings. Furthermore, it is likely that other factors such as rebinding combine to enhance the effect of residence time on the duration of signaling. Accordingly, we have devised a theoretical model that predicts a threshold residence time is needed to initiate SSIR but that rebinding is required to maintain it for the response duration observed in cellular experiments. This is based on several assumptions, thus necessitating further experimental work. In particular: does the agonist always need to remain bound; is agonist-receptor co-internalization essential for SSIR; and how valid is the concept of a requisite threshold residence time?
